1. Sędzikowska, A.; Szablewski, L. Insulin and Insulin Resistance in Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22(18), Art. No: 9987. DOI: 10.3390/ijms22189987
DOI: https://doi.org/10.3390/ijms22189987
2. Tokarz, V.L.; MacDonald, P.E.; Klip, A. The cell biology of systemic insulin function. J. Cell Biol. 2018, 217(7), 2273-2289. DOI: 10.1083/jcb.201802095
DOI: https://doi.org/10.1083/jcb.201802095
3. Hwang, H.G.; Kim, K.J.; Lee, S.H.; Kim, C.K.; Min, C.K.; Yun, J.M.; Lee S.U.; Son, Y.J. Recombinant Glargine Insulin Production Process Using Escherichia coli. J. Microbiol. Biotechnol. 2016, 26(10), 1781-1789. DOI: 10.4014/jmb.1602.02053
DOI: https://doi.org/10.4014/jmb.1602.02053
4. Mathieu, C.; Martens, P.J.; Vangoitsenhoven, R. One hundred years of insulin therapy. Nat. Rev. Endocrinol. 2021, 17(12), 715-725. DOI: 10.1038/s41574-021-00542-w
DOI: https://doi.org/10.1038/s41574-021-00542-w
5. Heise, T. The future of insulin therapy. Diabetes Res. Clin. Pract. 2021, 175, Art. No: 108820. DOI: 10.1016/j.diabres.2021.108820
DOI: https://doi.org/10.1016/j.diabres.2021.108820
6. Chen, W.; Cai, W.; Hoover, B.; Kahn, C.R. Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci. 2022, 45(5), 384-400. DOI: 10.1016/j.tins.2022.03.001
DOI: https://doi.org/10.1016/j.tins.2022.03.001
7. Akhtar, A.; Sah, S.P. Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease. Neurochem. Int. 2020, 135, Art. No: 104707. DOI: 10.1016/j.neuint.2020.104707
DOI: https://doi.org/10.1016/j.neuint.2020.104707
8. Tumminia, A.; Vinciguerra, F.; Parisi, M.; Frittitta, L. Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications. Int. J. Mol. Sci. 2018, 19(11), 3306. DOI: 10.3390/ijms19113306
DOI: https://doi.org/10.3390/ijms19113306
9. Biosa, A.; Outeiro, T.F.; Bubacco, L.; Bisaglia, M. Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View. Mol. Neurobiol. 2018, 55(11), 8754-8763. DOI: 10.1007/s12035-018-1025-9
DOI: https://doi.org/10.1007/s12035-018-1025-9
10. Hallschmid, M. Intranasal Insulin for Alzheimer's Disease. CNS Drugs 2021, 35(1), 21-37. DOI: 10.1007/s40263-020-00781-x
DOI: https://doi.org/10.1007/s40263-020-00781-x
11. Araszkiewicz, A.; Bandurska-Stankiewicz, E. et al. Zalecenia kliniczne dotyczące postępowania u osób z cukrzycą 2023 - Stanowisko Polskiego Towarzystwa Diabetologicznego. Curr. Top. Diabetes 2023, 3(1), 1-140
12. Yan, J.W.; Slim, A.; Van Aarsen, K.; Choi, Y.H.; Byrne, C.; Poonai, N.; Collins, H.; Clemens, K.K. Balanced crystalloids (RInger's lactate) versus normal Saline in adults with diabetic Ketoacidosis in the Emergency Department (BRISK-ED): a protocol for a pilot randomized controlled trial. Pilot Feasibility Stud. 2023, 9(1), Art. No: 121. DOI: 10.1186/s40814-023-01356-5
DOI: https://doi.org/10.1186/s40814-023-01356-5
13. Dunn, B. K.; Coore, H.; Bongu, N.; Brewer, K. L.; Kumar, D.; Malur, A.; Alkhalisy, H. Treatment Challenges and Controversies in the Management of Critically Ill Diabetic Ketoacidosis (DKA) Patients in Intensive Care Units. Cureus 2024, 16(9), Art. No: e68785. DOI: 10.7759/cureus.68785
DOI: https://doi.org/10.7759/cureus.68785
14. Catahay, J. A.; Polintan, E. T.; Casimiro, M.; Notarte, K. I.; Velasco, J. V.; Ver, A. T.; Pastrana, A.; Macaranas, I.; Patarroyo-Aponte, G.; Lo, K. B. Balanced Electrolyte Solutions Versus Isotonic Saline in Adult Patients With Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis. Heart Lung 2022, 54, 74–79. DOI: 10.1016/j.hrtlng.2022.03.014
DOI: https://doi.org/10.1016/j.hrtlng.2022.03.014
15. Thammakosol, K.; Sriphrapradang, C. Effectiveness and Safety of Early Insulin Glargine Administration in Combination With Continuous Intravenous Insulin Infusion in Management of Diabetic Ketoacidosis: A Randomized Controlled Trial. Diabetes, Obes. Metab. 2023, 25(3), 815-822. DOI: 10.1111/dom.14929
DOI: https://doi.org/10.1111/dom.14929
16. Gilbert, B. W.; Murray, D. S.; Cox, T. R.; He, J.; Wenski, A. M.; Qualls, K. E. What Are We Waiting For? A Review of Early Basal Insulin Therapy in Diabetic Ketoacidosis Management. Am. J. Emerg. Med. 2023, 72, 147–150. DOI: 10.1016/j.ajem.2023.07.049
DOI: https://doi.org/10.1016/j.ajem.2023.07.049
17. Dhatariya, K. K. The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet. Med. 2022, 39(6), Art. No: e14788. DOI: 10.1111/dme.14788
DOI: https://doi.org/10.1111/dme.14788
18. Lavonas, E. J.; Akpunonu, P. D.; Arens, A. M.; Babu, K. M.; Cao, D.; Hoffman, R. S.; Hoyte, C. O.; Mazer-Amirshahi, M. E.; Stolbach, A.; St-Onge, M.; i in. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2023, 148(16), 149-184. DOI: 10.1161/cir.0000000000001161
DOI: https://doi.org/10.1161/CIR.0000000000001161
19. Alshaya, O. A.; Alhamed, A.; Althewaibi, S.; Fetyani, L.; Alshehri, S.; Alnashmi, F.; Alharbi, S.; Alrashed, M.; Alqifari, S. F.; Alshaya, A. I. Calcium Channel Blocker Toxicity: A Practical Approach. J. Multidiscip. Healthc. 2022, 15, 1851–1862. DOI: 10.2147/jmdh.s374887
DOI: https://doi.org/10.2147/JMDH.S374887
20. Lott, C.; Truhlář, A.; Alfonzo, A.; Barelli, A.; González-Salvado, V.; Hinkelbein, J.; Nolan, J. P.; Paal, P.; Perkins, G. D.; Thies, K.-C.; i in. Corrigendum to “European Resuscitation Council Guidelines 2021: Cardiac Arrest in Special Circumstances” [Resuscitation 161 (2021) 152–219]. Resuscitation 2021, 167, 91–92. DOI: 10.1016/j.resuscitation.2021.08.012
DOI: https://doi.org/10.1016/j.resuscitation.2021.08.012
21. Cole, J.B.; Arens, A.M.; Laes, J.R.; Klein, L.R.; Bangh, S.A.; Olives, T.D. High dose insulin for beta-blocker and calcium channel-blocker poisoning. Am. J. Emerg. Med. 2018, 36(10), Art. No: 1817-1824. DOI: 10.1016/j.ajem.2018.02.004
DOI: https://doi.org/10.1016/j.ajem.2018.02.004
22. Lheureux, P.E.; Zahir, S.; Gris, M.; Derrey, A.S.; Penaloza, A. Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care. 2006, 10(3), Art. No: 212. DOI: 10.1186/cc4938
DOI: https://doi.org/10.1186/cc4938
23. Schult, R. F.; Nacca, N.; Grannell, T. L.; Jorgensen, R. M.; Acquisto, N. M. Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation. Am. J. Heal. Pharm. 2021, 79 (7), 547–555. DOI: 10.1093/ajhp/zxab439
DOI: https://doi.org/10.1093/ajhp/zxab439
24. Engebretsen, K. M.; Kaczmarek, K. M.; Morgan, J.; Holger, J. S. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin. Toxicol. 2011, 49(4), 277–283. DOI: 10.3109/15563650.2011.582471
DOI: https://doi.org/10.3109/15563650.2011.582471
25. Rotella, J.-A.; Greene, S. L.; Koutsogiannis, Z.; Graudins, A.; Hung Leang, Y.; Kuan, K.; Baxter, H.; Bourke, E.; Wong, A. Treatment for beta-blocker poisoning: a systematic review. Clin. Toxicol. 2020, 58(10), 943–983. DOI: 10.1080/15563650.2020.1752918
DOI: https://doi.org/10.1080/15563650.2020.1752918
26. Goldfine, C. E.; Troger, A.; Erickson, T. B.; Chai, P. R. Beta blocker and calcium channel blocker toxicity: Current evidence on evaluation and management. Eur. Heart J. Acute Cardiovasc. Care 2023, 13(2), 247-253. DOI: 10.1093/ehjacc/zuad138
DOI: https://doi.org/10.1093/ehjacc/zuad138
27. Greene, S. L.; Gawarammana, I.; Wood, D. M.; Jones, A. L.; Dargan, P. I. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007, 33(11), 2019–2024. DOI: 10.1007/s00134-007-0768-y
DOI: https://doi.org/10.1007/s00134-007-0768-y
28. Jessen, M. K.; Andersen, L. W.; Djakow, J.; Chong, N. K.; Stankovic, N.; Staehr, C.; Vammen, L.; Petersen, A. H.; Johannsen, C. M.; Eggertsen, M. A.; et al. Pharmacological Interventions for the Acute Treatment of Hyperkalaemia: A Systematic Review and Meta-analysis. Resuscitation 2025, 208, Art. No: 110489. DOI: 10.1016/j.resuscitation.2025.110489
DOI: https://doi.org/10.1016/j.resuscitation.2025.110489
29. LaRue, H. A.; Peksa, G. D.; Shah, S. C. A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency. Pharmacotherapy 2017, 37(12), 1516–1522. DOI: 10.1002/phar.2038
DOI: https://doi.org/10.1002/phar.2038
30. Garcia, J.; Pintens, M.; Morris, A.; Takamoto, P.; Baumgartner, L.; Tasaka, C. L. Reduced Versus Conventional Dose Insulin for Hyperkalemia Treatment. J. Pharm. Pract. 2018, 33(3), 262–266. DOI: 10.1177/0897190018799220
DOI: https://doi.org/10.1177/0897190018799220
31. Wheeler, D. T.; Schafers, S. J.; Horwedel, T. A.; Deal, E. N.; Tobin, G. S. Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia. J. Hosp. Med. 2016, 11(5), 355–357. DOI: 10.1002/jhm.2545
DOI: https://doi.org/10.1002/jhm.2545
32. Pierce, D. A.; Russell, G.; Pirkle, J. L. Incidence of Hypoglycemia in Patients With Low eGFR Treated With Insulin and Dextrose for Hyperkalemia. Ann. Pharmacother. 2015, 49(12), 1322–1326. DOI: 10.1177/1060028015607559
DOI: https://doi.org/10.1177/1060028015607559
33. Główny Inspektorat Sanitarny, Postępowanie w ostrych zatruciach fosforowodorem. Available online: https://www.gov.pl/web/gis/postepowanie-w-ostrych-zatruciach-fosforowodorem (accessed on 12.01.2025)
34. Shukla, R.; Lamichhane, K.; Pandey, D.; Gupta, C. K.; Shukla, S. Insulin in aluminum phosphide poisoning: A systematic review of the current literature. Medicine 2024, 103(42), Art. No: e40066. DOI: 10.1097/md.0000000000040066
DOI: https://doi.org/10.1097/MD.0000000000040066
35. Sedaghattalab, M. Treatment of critical aluminum phosphide (rice tablet) poisoning with high-dose insulin: a case report. J. Med. Case Rep. 2022, 16 (1), Art. No: 192. DOI: 10.1186/s13256-022-03425-4
DOI: https://doi.org/10.1186/s13256-022-03425-4
36. Hensher, C.; Vogel, J. High-Dose Insulin Euglycemic Therapy in the Treatment of a Massive Caffeine Overdose. Chest 2020, 157(5), e145-e149. DOI: 10.1016/j.chest.2019.11.030
DOI: https://doi.org/10.1016/j.chest.2019.11.030
37. Batista, M.; Dugernier, T.; Simon, M.; Haufroid, V.; Capron, A.; Fonseca, S.; Bonbled, F.; Hantson, P. The spectrum of acute heart failure after venlafaxine overdose. Clin. Toxicol. 2013, 51(2), 92–95. DOI: 10.3109/15563650.2012.763133
DOI: https://doi.org/10.3109/15563650.2012.763133
38. Stefani, M.; Roberts, D. M.; Brett, J. High-dose insulin euglycemic therapy to treat cardiomyopathy associated with massive venlafaxine overdose. Clin. Toxicol. 2019, 58(4), 299–300. DOI: 10.1080/15563650.2019.1638930
DOI: https://doi.org/10.1080/15563650.2019.1638930